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Now more than ever, the research community should be
concentrating on finding ways to reduce the incidence of
dementia. The population is aging, and the number of indi-
viduals affected by dementia remains a major public health
challenge. The reality is that we have no effective treatments
for dementia. In the absence
of treatments to cure the
disorder (or even reduce the
associated burden by delay-
ing onset or reducing disability), the prevention of dementia
must be a priority research topic. Modifiable risk factors are
associated with dementia1 (eg, diabetes and attendant
behavioral risks, such as diet and physical activity); these
risk factors are important but complex targets for interven-
tion. However, as with many neurologic and psychiatric dis-
orders, we have a scant appreciation of the environmental
risk factors that contribute to dementia risk. There is an
urgent need to generate new candidate risk factors for
dementia. In contrast to genetics, for which there are now
cost-efficient, high-throughput screening methods that can
generate genetic candidates, epidemiology relies on a mix of
creative researchers and access to suitable databases that
contain the variables of interest. Epidemiologists are envi-
ous of our colleagues in genetics, in which the search space
for risk variants is more tractable and bounded.
The study by Kessing and colleagues2 presents evidence
that low lithium concentration in the drinking water may be
associated with an increased risk of dementia. The hypoth-
esis is surprisingbut ismechanistically plausible. Thehypoth-
esisbuildsonpreliminaryevidence fromclinical trials that sug-
gest that lithium supplementation may improve cognitive
outcomes in groupswithmild cognitive impairment3 andAlz-
heimer disease.4 The new study links Danish health registers
witharea-level studies thatmapobservedand imputed lithium
concentrations in drinking water supplies.
The link between lithium and neuropsychiatry has a
venerable history. More than 50 years ago, Australian5 and
Danish psychiatrists6 pioneered the use of lithium as a treat-
ment for mania. Attempts have been made to reverse engi-
neer the neurobiology of bipolar disorder from the known
biological properties of lithium. However, lithium affects
many biological pathways linked to neuroprogressive and
neurodegenerative disorders.7 For example, lithium affects
diverse homeostatic mechanisms that include intracellular
calcium, microglial activation, glutamate excitotoxicity,
apoptosis and autophagy, inflammation, oxidative stress,
and mitochondrial dysfunction. Lithium increases synaptic
plasticity, potentially via mechanistic target of rapamycin
(mTOR), and upregulates several antiapoptotic factors, such
as Bcl-2. It also inhibits inositol monophosphatase 2 and
reduces myo-inositol 1,4,5-triphosphate levels. All these are
documented processes in dementia. Of note, lithium inhib-
its glycogen synthase kinase 3 (GSK-3) and inositol 1,4,5-
triphosphate. Expression of GSK3 is increased early in
dementia and plays a role in the hyperphosphorylation of
tau, in which GSK3 regulates the cleavage of amyloid pre-
cursor protein to increase amyloid Aβ production. Compli-
cating this further, all these pathways are intertwined. Nev-
ertheless, if the finding by Kessing and colleagues2 is
confirmed by replication, it will provide another clue to the
neurobiology of the disorder and may have translational
implications.
As Kessing and colleagues note,2 the findings should be
interpreted cautiously. The association may reflect unmea-
sured, region-varying confounding factors. In addition, non-
linear exposure-risk associations may be present: could
increasing the concentration of lithium in the drinking water
increase the risk in a subgroup of the population? We prefer
risk factors that translate to simple public health messages.
We also need to be confident that any putative benefits of
higher lithium concentrations in drinking water are not out-
weighed by unexpected adverse outcomes. That said, the
prospect that a relatively safe, simple, and cheap interven-
tion (ie, optimizing lithium concentrations in the drinking
water) could lead to the primary prevention of dementia is a
tantalizing prospect. In addition, higher concentration of
lithium in drinking water may have other neuropsychiatric
benefits. Although findings are inconsistent, some evidence
suggests that this exposure may also be associated with a
reduced risk of suicide.8,9 Lack of specificity with respect to
beneficial outcomes is an attractive feature from a public
health perspective; it could add to the denominator of ben-
efit in calculating the risk-benefit ratio.
If the findings of Kessing and colleagues2 are supported
in future studies, even a marginal reduction in the incidence
of dementia could result in major societal and economic
gains.10 However, we also need to consider the political and
social landscape regarding augmentation of drinking water
(such as the ongoing debate around fluoride and dental car-
ies). In thespirit of alchemy, couldweconvert lithium,a simple
metal usedas amood stabilizer, into a goldenpublic health in-
tervention that could prevent dementia? This will depend on
what the next generation of epidemiologic studies and clini-
cal trials reveal.
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